Overview

This study aims to evaluate and report the clinical adverse events and dosimetric parameters in breast cancer patients undergoing an "all-in-one (AIO)" one-stop, fully automated radiotherapy workflow. By systematically tracking these clinical and physical metrics, we seek to establish a standardized clinical protocol for AIO radiotherapy in breast cancer management.

Eligibility

Inclusion Criteria:

• Histologically or pathologically confirmed breast cancer with definitive indications for radiotherapy (preoperative, postoperative, or radical)
• ECOG performance status of 0-2
• Able to remain still and supine on the treatment couch for up to 30 minutes
• Provision of signed, written informed consent
• Able to comply with daily follow-ups and blood sample collections

Exclusion Criteria:

• Palliative radiotherapy for concurrent distant metastasis
• Incomplete or ongoing chemotherapy
• Synchronous multiple primary tumors
• Current pregnancy or lactation
• Prior history of radiotherapy to the ipsilateral breast, chest wall, thorax, or regional lymph nodes
• Severe non-malignant comorbidities (e.g., cardiovascular or pulmonary diseases, systemic lupus erythematosus, scleroderma) resulting in a short life expectancy or inability to tolerate radical radiotherapy
• Inability or unlikelihood to comply with study follow-up
• Inability or unwillingness to provide written informed consent